This suggests that high PTK6 expression may decrease the tumor’s immune evasion by suppressing immune checkpoint molecules, thereby enhancing the tumor microenvironment’s susceptibility to immune clearance during treatment. The gene discussed is PTK6; the disease is neoplasm.